PQQ: Mitochondrial Biogenesis and Brain Health
PQQ is sold on a mitochondrial biogenesis claim built from cell studies. The human trials are small, Japanese, and more interesting for sleep than for energy.
The Short Answer
Pyrroloquinoline quinone is a redox-active compound found in trace amounts in foods including fermented soy, kiwi and green tea, and it functions as a cofactor for bacterial dehydrogenases. It is marketed for mitochondrial biogenesis on the basis of cell and rodent work showing increased PGC-1 alpha signalling and higher mitochondrial content, and that mechanism has not been demonstrated in humans. The human trial literature is small, mostly conducted in Japan at 20 mg per day, and its more consistent findings concern sleep quality, fatigue and mood rather than energy or cognition. It is expensive per milligram and sits at Evidence Level B at best.
What PQQ Is
PQQ is an ortho-quinone, meaning it can cycle between oxidised and reduced states repeatedly without degrading, which makes it an unusually durable redox cofactor. In bacteria it serves as a genuine enzymatic cofactor. In mammals, whether it acts as a vitamin-like essential nutrient remains unresolved: it is not classified as a vitamin, no human insufficiency state has been established, and animals raised on PQQ-restricted diets show growth and reproductive impairments that have not translated into a defined human requirement.
What is agreed is that it is present in trace amounts in the diet, that it is absorbed, and that it is redox active at concentrations achievable through supplementation.
The Mitochondrial Biogenesis Claim
The claim traces to cell and rodent work in which PQQ increased expression of PGC-1 alpha, the master regulator of mitochondrial biogenesis, apparently through CREB signalling, with downstream increases in mitochondrial number and respiratory capacity in the cells and tissues receiving it.
Three qualifications matter. First, this is cell and animal work; no human study has measured mitochondrial content or biogenesis markers in tissue after PQQ supplementation. Second, PGC-1 alpha is activated far more powerfully by exercise, which is available, free and validated in humans. Third, several compounds raise PGC-1 alpha expression in cell culture without producing measurable human effects, so pathway activation is a starting point rather than a result.
PQQ has also been reported to stimulate nerve growth factor production in cell work, which is the basis for the brain health positioning, with the same caveat that human confirmation is absent.
What the Human Trials Show
The human literature comprises a handful of small trials, largely at 20 mg per day, mostly in Japanese cohorts.
Sleep and mood
The most consistent findings. Trials report improvements in sleep quality measures, reduced sleep onset latency, lower fatigue and improved mood scores over eight weeks at 20 mg per day, with corresponding changes in salivary cortisol patterns in one study. These are small trials with subjective primary outcomes, and they are the most replicated part of the PQQ literature.
Cognitive measures
Small trials report improvements in some memory and attention measures in older adults, with inconsistent domains across studies. A trial combining PQQ with CoQ10 reported larger effects than either alone on a memory composite, which is the basis for the common pairing.
Inflammatory and metabolic markers
Single trials report reductions in C-reactive protein and changes in some metabolic markers. Not replicated.
Exercise performance
Little support. Trials examining aerobic capacity or performance outcomes have generally been null.
The honest summary: a small, geographically concentrated evidence base with its most consistent signal in sleep and fatigue, and no human confirmation of the mitochondrial mechanism it is sold on.
Dose, Form and Cost
- 10 to 20 mg per day. The range used in essentially all human trials. There is no evidence that more is better, and doses above this range have not been studied for efficacy.
- Disodium salt. The common commercial form, which is stable and water soluble. Trials used this form.
- Timing. Trials used once-daily dosing without particular timing requirements. Given the sleep findings, evening dosing is a reasonable choice for that objective, though the trials that found sleep effects did not specify timing as a variable.
- Cost. PQQ is among the more expensive supplements per effective dose, which matters when the evidence is thin. A member paying a premium for a mitochondrial claim with no human data is buying a hypothesis.
The CoQ10 pairing is common and has one supporting trial. Both compounds are mitochondria-adjacent, and CoQ10 has the substantially stronger evidence base, so the pairing is best understood as CoQ10 with an addition rather than the reverse.
Safety
PQQ appears well tolerated. Trials at 20 mg per day for eight to twelve weeks report no consistent adverse effects, and higher single doses in tolerability studies have been unremarkable apart from occasional headache and gastrointestinal discomfort.
Two notes. Long-term safety is unestablished, as with most compounds in this category, since no trial has run for years. And PQQ is redox active, which places it in the same general category as other antioxidant compounds with respect to the training window: there is no specific evidence of interference, and the conservative approach is to avoid stacking high-dose redox-active compounds immediately around hard sessions.
How to Judge It
PQQ is a compound where the marketing claim and the evidence point in different directions, which makes the decision unusually clean once that is recognised.
If the objective is mitochondrial biogenesis, the honest answer is that exercise does this powerfully and demonstrably in humans, while PQQ has shown it only in cell culture. Choosing PQQ instead of training is the wrong trade; buying it in addition to training is buying a hypothesis at a premium.
If the objective is sleep quality or fatigue, the evidence is thin but it is the strongest part of the literature, the dose is well defined at 20 mg per day, and eight weeks is a fair test with a perceptible endpoint. That is a defensible experiment.
Either way, this is a second-layer compound at best. It does not belong in a foundational stack, and the review point should be set at eight to twelve weeks against a stated objective, with removal as the default outcome if nothing changed.
The AEONNN Perspective
PQQ illustrates a specific failure mode AEONNN is built to prevent: a compound sold on a mechanism that has only been shown in cells, while its actual human signal lies somewhere else entirely. A system that indexed mechanism would rank it for Cellular Energy. A system that reads the Evidence layer honestly places its best-supported use in Sleep and Circadian Regulation.
It maps primarily to Cellular Energy and Repair and secondarily to Cognition and Neuroprotection, and Insight Protocol presents the mitochondrial claim with its confidence stated: mechanistic, animal and cell only. Where a member's objective is mitochondrial capacity, the higher-value recommendation is a training structure, and saying so is the point of ranking behavioural interventions above compounds.
Cost enters the reasoning too. PQQ is expensive per effective dose, and a platform that ignores cost while stacking marginal compounds is not reasoning about a real member's constraints.
Pillar Matrix mapping
Database Matrix layers
- Mechanistic Layer (KEGG, Reactome, UniProt)
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Safety Layer (DrugBank, FAERS)
- Quality / Formulation Layer (ConsumerLab, Labdoor)
- Innovation Layer (bioRxiv preprints, patent filings)
Frequently Asked
Does PQQ actually increase mitochondrial numbers in humans?
Not demonstrated. The biogenesis claim comes from cell and rodent work showing increased PGC-1 alpha signalling. No human study has measured mitochondrial content or biogenesis markers after supplementation.
How much PQQ should be taken?
Essentially all human trials used 10 to 20 mg per day. There is no evidence that higher doses do more, and they have not been studied for efficacy.
What is PQQ best supported for?
Sleep quality, fatigue and mood, which is the most replicated part of a small literature, with trials at 20 mg per day over eight weeks. This is not what it is usually marketed for.
Is the PQQ and CoQ10 combination worth it?
One trial reported larger effects on a memory composite than either alone. CoQ10 has substantially stronger independent evidence, so the pairing is best read as CoQ10 plus an addition.
Is PQQ a vitamin?
No. It is not classified as a vitamin, no human insufficiency state has been established, and whether it acts as an essential nutrient in mammals remains unresolved.
When should PQQ be taken?
Trials did not test timing as a variable. Given that the sleep findings are its strongest signal, evening dosing is a reasonable choice for that objective.
Is PQQ safe?
Trials at 20 mg per day over eight to twelve weeks report no consistent adverse effects. Long-term safety is unestablished, as for most compounds in this category.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.